Our Science

FSD Pharma is taking a diversified approach to deliver “Total Brain Health” to patients in need. Our mission is to treat the millions of people suffering from neurodegenerative and neuropsychiatric diseases by bringing innovative therapies to market. Through our wholly-owned subsidiary, Lucid Psycheceuticals, we have the exclusive worldwide rights to patented CNS compounds with the potential to treat the underlying cause of progressive Multiple Sclerosis (“MS”). Additionally, FSD is developing a unique psychedelic-based therapeutic aimed to address a multibillion-dollar mental health market.

FSD Pharma has a pipeline of the following 3 drug candidates:

1.FSD-PEA (Formerly known as FSD-201 )

FSD-PEA is an anti-inflammatory compound

FSD Pharma is currently assessing next steps for FSD-PEA, an ultra micro-PEA compound with anti-inflammatory properties shown to be safe following positive Phase 1 clinical results. FSD-PEA has the potential to address a range of inflammatory conditions. FSD Pharma is currently analyzing what is the best indication to go for a Phase 2 trial.

2.Lucid-MS (patented New Chemical Entity (NCE))

Lucid-MS is Neuroprotective compound which, in pre-clinical models, has shown to prevent and reverse Myelin degradation, which is a cause for Multiple Sclerosis as well as other Neuro-degenerative disorders

3.Lucid-Psych (Psychedelic or psychoactive)

Lucid-PSYCH is a psycho-active molecule